Get 40% Off
👀 👁 🧿 All eyes on Biogen, up +4,56% after posting earnings. Our AI picked it in March 2024.
Which stocks will surge next?
Unlock AI-picked Stocks

CureVac Jumps on EU Vaccine Talks Days After Sky-High IPO

Published 08/20/2020, 10:30 AM
Updated 08/20/2020, 10:31 AM
© Shutterstock

By Christiana Sciaudone

Investing.com --   CureVac jumped 14% after the EU concluded a first round of talks for 225 million doses of a potential Covid-19 vaccine.

Curevac Bv (NASDAQ:CVAC) went public on Aug. 14, when it soared almost 250%. The company, backed by the Bill & Melinda Gates Foundation, is focused on using messenger RNA to treat diseases. The IPO raised more than $213 million.

The EU is also in talks with Johnson & Johnson (NYSE:JNJ) and Sanofi (NASDAQ:SNY) for their vaccines under development, and agreed last week an advanced purchase deal with AstraZeneca (NYSE:AZN) for at least 300 million doses of the shot it is developing with Oxford University, Reuters reported. CureVac said the talks included an option to supply 180 million additional doses.

 

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.